Blood Res.  2015 Mar;50(1):58-61. 10.5045/br.2015.50.1.58.

Chronic eosinophilic leukemia with a FIP1L1-PDGFRA rearrangement: Two case reports and a review of Korean cases

• Shin SY
• Jung CW
• Choi DC
• Lee BJ
• Kim HJ
• Kim SH

• KMID: 1787916
• DOI: http://doi.org/10.5045/br.2015.50.1.58

Abstract

No abstract available.

MeSH Terms

Hypereosinophilic Syndrome*

Figure

• 

  Fig. 1 Peripheral blood (PB) smear and bone marrow (BM) aspirate findings of first case (A, B) and second case (C, D). (A) Eosinophilia (13.0×109/L) was observed in the PB (Wright-Giemsa, ×1,000). (B) Dysplastic eosinophils (sparse and mixed granules) were increased in the BM aspirate (Wright-Giemsa, ×1,000). (C) Eosinophilia (55.316×109/L) was observed in the PB (Wright-Giemsa, ×1,000). (D) The BM section was packed with eosinophils (hematoxylin-eosin, ×400).

• 

  Fig. 2 Fluorescence in situ hybridization (FISH) for the FIP1L1-PDGFRA rearrangement, and reverse transcription - polymerase chain reaction (RT-PCR) and sequencing analysis. (A) Schematic representation of the 4q12 region and FISH probe. (B) Loss of the orange signal indicates deletion of the 4q12 region (white arrow) in first case. (C) FISH results for second case. (D) RT-PCR was performed using RNA extracted from the patient's (first case) white blood cells (lane 1). EOL-1 cells were used as a positive control (lane 2). Size marker (M). (E) Sequencing analysis of the RT-PCR products revealed the fusion of FIP1L1, exon 12 and truncated PDGFRA, exon 12 (breakpoint is between the 84th and 85th nucleotides of exon 12). FIP1L1, Ensemble Gene ID ENSG00000145216; PDGFRA, Ensemble Gene ID, ENSG00000134853.

Reference

1. Swerdlow SH, Campo E, Harris NL, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press;2008.

2. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 2003; 102:3093–3096. PMID: 12842979.

3. Gotlib J, Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia. 2008; 22:1999–2010. PMID: 18843283.

4. Kim DW, Shin MG, Yun HK, et al. Incidence and causes of hypereosinophilia (corrected) in the patients of a university hospital. Korean J Lab Med. 2009; 29:185–193. PMID: 19571614.

5. Park TS, Song J, Kim JS, et al. 8p11 myeloproliferative syndrome preceded by t(8;9)(p11;q33), CEP110/FGFR1 fusion transcript: morphologic, molecular, and cytogenetic characterization of myeloid neoplasms associated with eosinophilia and FGFR1 abnormality. Cancer Genet Cytogenet. 2008; 181:93–99. PMID: 18295660.

6. Kim M, Lim J, Lee A, et al. A case of chronic myelomonocytic leukemia with severe eosinophilia having t(5;12)(q31;p13) with t(1;7)(q10;p10). Acta Haematol. 2005; 114:104–107. PMID: 16103634.

7. Lee H, Kim M, Lim J, et al. Acute myeloid leukemia associated with FGFR1 abnormalities. Int J Hematol. 2013; 97:808–812. PMID: 23609419.

8. Jang SE, Kang HJ, Chang YH, et al. A case of myeloid neoplasm with the PDGFRB rearrangement and eosinophilia. Korean J Med. 2010; 78:386–390.

9. Lim KS, Ko J, Lee SS, Shin B, Choi DC, Lee BJ. A case of idiopathic hypereosinophilic syndrome presenting with acute respiratory distress syndrome. Allergy Asthma Immunol Res. 2014; 6:98–101. PMID: 24404401.

10. Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009; 124:1319–1325. PMID: 19910029.